Bausch Health Companies Inc. (NYSE:BHC) Director John Paulson Buys 754,134 Shares

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson purchased 754,134 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was purchased at an average cost of $5.05 per share, for a total transaction of $3,808,376.70. Following the transaction, the director now owns 27,193,169 shares of the company's stock, valued at approximately $137,325,503.45. This trade represents a 2.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson acquired 1,005,376 shares of Bausch Health Companies stock. The stock was bought at an average price of $5.47 per share, for a total transaction of $5,499,406.72.
• On Wednesday, June 11th, John Paulson acquired 1,029,098 shares of Bausch Health Companies stock. The stock was bought at an average price of $5.24 per share, for a total transaction of $5,392,473.52.

Bausch Health Companies Trading Up 9.2%

NYSE BHC traded up $0.51 on Friday, hitting $6.02. 11,490,808 shares of the company were exchanged, compared to its average volume of 2,611,854. The firm has a 50 day moving average of $4.85 and a two-hundred day moving average of $6.41. The company has a market cap of $2.23 billion, a P/E ratio of -50.12, a P/E/G ratio of 0.37 and a beta of 0.28. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Analysts Set New Price Targets

BHC has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nomura Holdings Inc. lifted its position in Bausch Health Companies by 106.2% during the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock worth $151,366,000 after buying an additional 12,050,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in Bausch Health Companies by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock worth $76,152,000 after purchasing an additional 61,621 shares during the last quarter. Franklin Resources Inc. raised its holdings in Bausch Health Companies by 1.1% during the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after purchasing an additional 56,446 shares during the last quarter. Maple Rock Capital Partners Inc. raised its holdings in Bausch Health Companies by 156.7% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after purchasing an additional 3,235,100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Bausch Health Companies by 46.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after purchasing an additional 1,510,445 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.